The Alb-R26Met liver cancer mouse model recapitulates molecular features and heterogeneity of hepatocellular carcinoma patients
RNA-seq (gene expression) · mouse · 18 samples
- What it is
- RNA-seq (gene expression)Gene activity measured by sequencing. The summary does not mention single-cell work, so this is most likely bulk: one average per sample, the usual starting point for comparing groups.
- Organism
- Mus musculus (mouse)
- Samples
- 18 samples: 12 × advanced liver tumour AlbR26Met vs 6 × mutant liver healty AlbR26MetGroups are read from the sample names, not from the paper. Check the list below.
- Data you can get
- A processed table (series matrix) and supplementary files from NCBI; the raw sequencing reads from ENA. Which of these hold counts depends on the study, so check the file list.
- Paper
- Tracing specificity of immune landscape remodeling associated with distinct anticancer treatmentsiScience · 2025
Read the full summary ↓
Direct links to NCBI and ENA, no account and no request form. Pick by what you want to do: take the small processed table to look, the supplementary files to re-analyse, or the original raw data to start over.
Processed table
The series matrix: one table of values per sample as the submitters processed it. The smallest download, and it opens in Excel or R. Start here to see what the data look like.
Supplementary files
The count tables and other files the authors uploaded. Take only the samples you need, or the whole study as GSE271709_RAW.tar (it can run to tens of gigabytes).
Raw sequencing reads
The original FASTQ files, straight from the sequencer, held at ENA. Large, and you align them yourself, so only choose this if you need to re-process the study from scratch.
What the files usually look like: For RNA-seq the counts are usually a table among the supplementary files (look for 'counts', 'expression', 'FPKM' or 'TPM' in the file name). The series matrix of a sequencing study is sometimes nearly empty.
Also filed as BioProject PRJNA1132968 and SRA study SRP518522. Searching any of these in the dataset finder brings you back here.
Supports a between-group comparison across 18 samples.
How we read this: 2 replicated groups read from 18 sample titles; they account for 18 of them. These groups are guessed from the sample names, not taken from the paper, so check them against the sample list below before relying on them.
- GSM8383206 mutant liver healty AlbR26Met_6 mutant liver healty Alb…
- GSM8383207 mutant liver healty AlbR26Met_5 mutant liver healty Alb…
- GSM8383208 mutant liver healty AlbR26Met_4 mutant liver healty Alb…
- GSM8383209 mutant liver healty AlbR26Met_3 mutant liver healty Alb…
- GSM8383210 mutant liver healty AlbR26Met_2 mutant liver healty Alb…
- GSM8383211 mutant liver healty AlbR26Met_1 mutant liver healty Alb…
- GSM8383212 advanced liver tumour AlbR26Met_9 advanced liver tumour A…
- GSM8383213 advanced liver tumour AlbR26Met_8 advanced liver tumour A…
- GSM8383214 advanced liver tumour AlbR26Met_7 advanced liver tumour A…
- GSM8383215 advanced liver tumour AlbR26Met_6 advanced liver tumour A…
- GSM8383216 advanced liver tumour AlbR26Met_5 advanced liver tumour A…
- GSM8383217 advanced liver tumour AlbR26Met_4 advanced liver tumour A…
- GSM8383218 advanced liver tumour AlbR26Met_3 advanced liver tumour A…
- GSM8383219 advanced liver tumour AlbR26Met_2 advanced liver tumour A…
- GSM8383220 advanced liver tumour AlbR26Met_12 advanced liver tumour A…
- GSM8383221 advanced liver tumour AlbR26Met_11 advanced liver tumour A…
- GSM8383222 advanced liver tumour AlbR26Met_10 advanced liver tumour A…
- GSM8383223 advanced liver tumour AlbR26Met_1 advanced liver tumour A…
- GSE230972 Loss of cisPTase function in the liver promotes a highly penetrant form of fatty liver disease that rapidly transitions to hepatocellular carcinoma 27 samples shares hepatocellular, liver
- GSE271243 Berberine protects against hepatocellular carcinoma progression by regulating intrahepatic T cell heterogeneity 18 samples shares hepatocellular, heterogeneity
- GSE242852 Perilipin 5 deletion protects against nonalcoholic fatty liver disease and hepatocellular carcinoma by modulating lipid metabolism and inflammatory responses 18 samples shares hepatocellular, liver
- GSE230838 Loss of cisPTase function in the liver promotes a highly penetrant form of fatty liver disease that rapidly transitions to hepatocellular carcinoma [RNA-seq] 17 samples shares hepatocellular, liver
- GSE291163 Testing the contribution of FGL1 to the pathogenesis of metabolic dysfunction-associated steatotic liver disease and hepatocellular carcinoma 16 samples shares hepatocellular, liver
- GSE300751 CDK16 and CDK18 inhibition suppresses nuclear pore-mediated DNA repair and hepatocellular carcinoma [liver tumor] 14 samples shares hepatocellular, liver
- GSE246213 A Mouse Model for Metabolic Dysfunction-associated Steatotic Liver Disease and Hepatocellular Carcinoma [ATAC-seq] 12 samples shares hepatocellular, liver
- GSE302836 Loss of Hepatocyte PI3Ka Protects Mice from Hepatocellular Carcinoma in association with altered lipid metabolism gene expression 42 samples shares hepatocellular
Metadata from NCBI GEO, cached and refreshed periodically — the NCBI page above is authoritative. Downloads link straight to NCBI/ENA; nothing is proxied through BioTransfer.